| Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA. | |
| | |
MedLine Citation:
|
PMID: 23055389 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cetuximab (Erbitux(®)) is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). In the USA, the approval of cetuximab has been recently expanded to include the first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer (mCRC) when used in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin [folinic acid]). The addition of cetuximab to first-line treatment with FOLFIRI improved progression-free survival, overall survival, and objective response rates relative to treatment with FOLFIRI alone in patients with EGFR-expressing mCRC with KRAS wild-type tumors. Therefore, cetuximab plus FOLFIRI is a useful biomarker-directed option in the first-line treatment of this patient population. |
| | |
Authors:
|
Katherine A Lyseng-Williamson |
Related Documents
:
|
8423019 - A new aggressive treatment approach to high-grade endometrial cancer of possible benefi... 19471649 - Adjuvant therapy in high-risk early endometrial carcinoma: a retrospective analysis of ... 20660059 - Treatment for advanced and recurrent endometrial carcinoma: combined modalities. 10534159 - Clinical relevance of the histological classification of sinonasal intestinal-type aden... 17547889 - Stage iii endometrial cancer: preoperative predictability, prognostic factors, and trea... 1659199 - Postpartum vaginal atrophy. 7888829 - Current status and future perspectives in the treatment of low-grade non-hodgkin's lymp... 9283919 - Long-term survival in a case of high-risk type igd myeloma; a possibility of effectiven... 10493029 - Endobronchial metastatic disease. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Molecular diagnosis & therapy Volume: 16 ISSN: 1179-2000 ISO Abbreviation: Mol Diagn Ther Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-19 Completed Date: 2013-03-28 Revised Date: 2013-05-16 |
Medline Journal Info:
|
Nlm Unique ID: 101264260 Medline TA: Mol Diagn Ther Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 317-22 Citation Subset: IM |
Affiliation:
|
Adis, Auckland, New Zealand. mdt@adis.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
therapeutic use* Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Camptothecin / analogs & derivatives, therapeutic use Colorectal Neoplasms / drug therapy*, pathology Disease-Free Survival Fluorouracil / therapeutic use Gene Expression Regulation, Neoplastic Guidelines as Topic Humans Leucovorin / therapeutic use Mutation Neoplasm Metastasis Proto-Oncogene Proteins / genetics, metabolism Receptor, Epidermal Growth Factor / antagonists & inhibitors, genetics, metabolism ras Proteins / genetics, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/KRAS protein, human; 0/Proto-Oncogene Proteins; 0/cetuximab; 51-21-8/Fluorouracil; 58-05-9/Leucovorin; 7689-03-4/Camptothecin; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 3.6.5.2/ras Proteins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Significance of plasma osteopontin levels in patients with bladder urothelial carcinomas.
Next Document: Large enhancement of oscillating chemiluminescence with [Ru(bpy)(3) ](2+) -catalyzed Belousov-Zhabot...